The results of this paper showed that among breast cancers of different molecular stages, IL-6, IL-17 and VEGF were significantly higher in the breast cancer group than in the group with benign breast disease, and IL-17 and VEGF were higher in the HER-2 receptor-expressing and triple-negative types than in the hormone receptor-positive group. The gene discussed is IL17A; the disease is breast carcinoma.